← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA1021.7x27.0x44.6x
EV / LTM revenue161.5x2.1x4.2x
Premium to unaffected price1926%32%51%
Premium to 30-day VWAP0Too thin to quote. Widen the cut.

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
0362009: 1 deals, 0 clean on every measure200912010: 6 deals, 0 clean on every measure201062011: 6 deals, 1 clean on every measure201162012: 1 deals, 1 clean on every measure201212013: 3 deals, 2 clean on every measure201332014: 2 deals, 0 clean on every measure201422016: 4 deals, 4 clean on every measure201642017: 1 deals, 0 clean on every measure201712018: 2 deals, 1 clean on every measure201822019: 1 deals, 1 clean on every measure201912020: 2 deals, 1 clean on every measure202022022: 1 deals, 1 clean on every measure202212023: 1 deals, 1 clean on every measure202312024: 4 deals, 2 clean on every measure202442025: 3 deals, 2 clean on every measure202532026: 1 deals, 1 clean on every measure20261
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 26.6x median across 7 dealsHealthcare26.6xn=7
Deals by sector
Healthcare: 27 dealsHealthcare27Industrials: 11 dealsIndustrials11Technology: 1 dealsTechnology1
Deals by buyer type
Financial sponsor: 2 dealsFinancial sponsor2Strategic: 91 dealsStrategic91Management / founder: 0 dealsManagement / founder0Controlling holder: 0 dealsControlling holder0Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 39 dealsUnclassified39
Deals by enterprise value
Under $250m: 19 dealsUnder $250m19$250m to $1bn: 6 deals$250m to $1bn6$1bn to $5bn: 10 deals$1bn to $5bn10$5bn to $20bn: 3 deals$5bn to $20bn3Over $20bn: 1 dealsOver $20bn1Not computed: 0 dealsNot computed0
Deals by industry code
Business Services & Software: 162 dealsBusiness Services & Sof…162Chemicals, Pharmaceuticals & Allied Products: 87 dealsChemicals, Pharmaceutic…87Depository Institutions: 72 dealsDepository Institutions72Holding & Other Investment Offices: 53 dealsHolding & Other Investm…53Instruments, Medical Devices & Optical Goods: 39 dealsInstruments, Medical De…39Electronics & Electrical Equipment: 35 dealsElectronics & Electrica…35Electric, Gas & Sanitary Services: 33 dealsElectric, Gas & Sanitar…33Oil & Gas Extraction: 27 dealsOil & Gas Extraction27Insurance Carriers: 27 dealsInsurance Carriers27Communications: 26 dealsCommunications26
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Avanos Medical, Inc.
2026-04-13 · Public merger · $25.00 a share
A-AV Holdco I, Inc.
Unclassified
Healthcare$1.2bnn.a.1.7x
n.a.
DEFM14A
All cash
Hologic Inc
2025-10-21 · Public merger · $76.00 a share
Hopper Parent Inc.
Unclassified
Healthcare$17bn17.0x4.2x
27%
DEFM14A
All cash
ZimVie Inc.
2025-07-20 · Public merger · $19.00 a share
Zamboni Parent Inc.
Unclassified
Healthcare$681m26.6x1.5x
65%
DEFM14A
All cash
Akoya Biosciences, Inc.
2025-01-09 · Public merger · $4.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Industrials$239mn.a.2.9x
24%
DEFM14A
Includes stock
Singular Genomics Systems, Inc.
2024-12-22 · Public merger · $20.00 a share
Singular Genomics Parent, LLC
Unclassified
Industrials-$53mn.a.-19.7x
n.a.
DEFM14A
All cash
NeuroMetrix, Inc.
2024-12-17 · Public merger · $4.70 a share
Not named in the filing
Unclassified
Healthcare$9mn.a.2.3x
n.a.
DEFM14A
All cash
Surmodics Inc
2024-07-08 (filed) · Public merger · $43.00 a share
Held out of the multiples: EV / LTM EBITDA 503.8x outside 1x to 75x
Not named in the filing
Unclassified
Healthcare$605m503.8x5.0x
n.a.
DEFM14A
All cash
FG Group Holdings Inc.
2024-01-29 (filed) · Public merger · $1.60 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$33m66.4x0.7x
n.a.
DEFM14A
Includes stock
Conformis Inc
2023-06-22 · Public merger · $2.27 a share
Not named in the filing
Unclassified
Healthcare-$0mn.a.0.0x
50%
93% to VWAP
DEFM14A
All cash
Natus Medical Inc
2022-04-17 · Public merger · $33.50 a share
Prince Parent Inc.
Unclassified
Healthcare$1.1bn21.0x2.2x
29%
DEFM14A
All cash
Mts Systems Corp
2020-12-08 · Public merger · $58.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Industrials$1.6bnn.a.1.9x
52%
DEFM14A
Includes stock
Wright Medical Group N.V.
2020-03-20 (filed) · Public merger · $30.75 a share
Not named in the filing
Unclassified
Healthcare$5.0bn65.5x5.4x
n.a.
50% to VWAP
DEFM14A
All cash
Sierra Monitor Corp /Ca/
2019-03-28 · Public merger · $3.25 a share
Not named in the filing
Unclassified
Industrials$30m60.6x1.4x
51%
DEFM14C
All cash
Adynxx, Inc.
2018-10-11 · Public merger · $5.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$14mn.a.1.9x
n.a.
DEFM14A
Includes stock
Adynxx, Inc.
2018-03-30 (filed) · Public merger · $3.60 a share
Not named in the filing
Unclassified
Healthcare$38mn.a.1.9x
n.a.
DEFM14A
All cash
Zeltiq Aesthetics Inc
2017-02-13 · Public merger · $56.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM EBITDA 130.3x outside 1x to 75x
Allergan Holdco US, Inc.
Unclassified
Healthcare$2.2bn130.3x6.2x
14%
DEFM14A
Includes stock
Fei Co
2016-05-26 · Public merger · $107.50 a share
Not named in the filing
Unclassified
Industrials$4.1bn23.7x4.3x
16%
DEFM14A
All cash
Symmetry Surgical Inc.
2016-05-02 · Public merger · $13.10 a share
Not named in the filing
Unclassified
Healthcare$129m49.8x1.5x
n.a.
DEFM14A
All cash
Hansen Medical Inc
2016-04-19 · Public merger · $4.00 a share
Not named in the filing
Unclassified
Healthcare$97mn.a.7.3x
40%
DEFM14A
All cash
Affymetrix Inc
2016-01-08 · Public merger · $14.00 a share
Not named in the filing
Unclassified
Industrials$1.1bn29.2x3.1x
50%
DEFM14A
All cash
Covidien plc
2014-11-21 (filed) · Public merger · $35.19 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$19bn7.5xn.a.
n.a.
DEFM14A
Includes stock
Medtronic Inc
2014-11-21 (filed) · Public merger · $35.19 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$34bnn.a.1.9x
n.a.
DEFM14A
Includes stock
Rochester Medical Corporation
2013-09-03 · Public merger · $20.00 a share
Not named in the filing
Unclassified
Healthcare$228m27.5xn.a.
n.a.
DEFM14A
All cash
Aradigm Corp
2013-06-24 (filed) · Public merger · $0.12 a share
Not named in the filing
Unclassified
Healthcare$27mn.a.26.6x
n.a.
DEFM14A
All cash
Palomar Medical Technologies LLC
2013-03-17 · Public merger · $6.83 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Plan of Merger
Unclassified
Healthcare$48mn.a.0.6x
14%
DEFM14A
Includes stock

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More